Neurogene Inc. Common Stock (NGNE)
NGNE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$21.56
-11.78% on the day
Market cap
$431.4M
Small cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$90.4M
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | NGNE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | 2014 |
| SEC CIK | 0001404644 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$90.4M |
| Operating income | -$103.3M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $103.8M |
| Total assets | $288.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-07-02 |
| Latest annual report | 10-K | 2026-03-24 |
| Latest quarterly / interim | 10-Q | 2026-08-11 |
| Latest current report | 8-K | 2026-08-11 |
| Latest proxy | DEFA14A | 2026-04-16 |
Source: SEC EDGAR submissions feed, 750 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -17.3% |
| 1 month | -36.5% |
| 3 months | -41.4% |
| Year to date | +3.9% |
| 1 year | -32.3% |
| From 52-week high | -50.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PRTA | Prothena Corporation plc | $8.36 | -0.83% | $429.2M |
| OVID | Ovid Therapeutics Inc. | $2.19 | -9.13% | $427.7M |
| DMAC | DiaMedica Therapeutics Inc. | $7.82 | -4.63% | $421.7M |
| KMDA | Kamada Ltd. | $7.69 | -1.91% | $443.8M |
| RZLT | Rezolute Inc. Common Stock (NV) | $4.61 | -5.34% | $445.9M |
| ARVN | Arvinas Inc. | $6.84 | -8.19% | $447.2M |
| ASMB | Assembly Biosciences Inc. | $20.34 | -10.67% | $414.1M |
| SPRY | ARS Pharmaceuticals Inc. | $4.05 | -3.11% | $402.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier